
Promising drug target
Credit: EMBL/Pepperkok
“Inhibiting DGKi seems to reverse the effects of cystic fibrosis”
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis. Their work, published online today in Cell, also uncovers a large set of genes not previously linked to the disease, demonstrating how a new screening technique can help identify new drug targets.
Cystic fibrosis is a hereditary disease caused by mutations in a single gene called CFTR. These mutations cause problems in various organs, most notably making the lining of the lungs secrete unusually thick mucus. This leads to recurrent life-threatening lung infections, which make it increasingly hard for patients to breathe. The disease is estimated to affect 1 in every 2500-6000 newborns in Europe.
In patients with cystic fibrosis, the mutations to CFTR render it unable to carry out its normal tasks. Among other things, this means CFTR loses the ability to control a protein called the epithelial sodium channel (ENaC). Released from CFTR’s control, ENaC becomes hyperactive, cells in the lungs absorb too much sodium and – as water follows the sodium – the mucus in patients’ airways becomes thicker and the lining of the lungs becomes dehydrated. The only drug currently available that directly counteracts a cystic fibrosis-related mutation only works on the three percent of patients that carry one specific mutation out of the almost 2000 CFTR mutations scientists have found so far.
Thus, if you were looking for a more efficient way to fight cystic fibrosis, finding a therapy that would act upon ENaC instead of trying to correct that multitude of CFTR mutations would seem like a good option. But unfortunately, the drugs that inhibit ENaC, mostly developed to treat hypertension, don’t transfer well to cystic fibrosis, where their effects don’t last very long. So scientists at EMBL, Regensburg University and University of Lisboa set out to find alternatives.
“In our screen, we attempted to mimic a drug treatment,” says Rainer Pepperkok, whose team at EMBL developed the technique, “we’d knock down a gene and see if ENaC became inhibited.”
Starting with a list of around 7000 genes, the scientists systematically silenced each one, using a combination of genetics and automated microscopy, and analysed how this affected ENaC. They found over 700 genes which, when inhibited, brought down ENaC activity, including a number of genes no-one knew were involved in the process. Among their findings was a gene called DGKi. When they tested chemicals that inhibit DGKi in lung cells from cystic fibrosis patients, the scientists discovered that it appears to be a very promising drug target.
“Inhibiting DGKi seems to reverse the effects of cystic fibrosis, but not block ENaC completely,” says Margarida Amaral from the University of Lisboa, “indeed, inhibiting DGKi reduces ENaC activity enough for cells to go back to normal, but not so much that they cause other problems, like pulmonary oedema.”
The Latest Bing News on:
Cystic fibrosis
- New genetic disorder that causes susceptibility to opportunistic infectionson January 21, 2023 at 3:03 pm
Immunogeneticists have discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including a life-threatening fungal pneumonia.
- Cystic fibrosis: limiting the harmful adhesion of bacteriaon January 20, 2023 at 1:52 am
Biologists from the UNIGE Faculty of Medicine have discovered pharmacological inhibitors that limit the development of bacterial infections in the cells of people with cystic fibrosis. These results ...
- Cystic Fibrosis Carrier: What You Need to Knowon January 19, 2023 at 4:00 pm
What is a cystic fibrosis carrier? Cystic fibrosis is an inherited disease that affects the glands that make mucus and sweat. Children may be born with cystic fibrosis if each parent carries one ...
- Is Cystic Fibrosis Contagious?on January 19, 2023 at 4:00 pm
Cystic fibrosis is an inherited genetic condition. It’s not contagious. To have the disease, you must inherit the faulty cystic fibrosis gene from both parents. The disease causes the mucus in ...
- Cystic fibrosis: preventing bacteria from docking to the airwayson January 19, 2023 at 10:08 am
Cystic fibrosis: preventing bacteria from docking to the airways. Cystic fibrosis is a genetic disease that causes severe respiratory complications. Despite many therapeutic advan ...
- Cystic Fibrosis (CF) Therapeutics Market to Grow Significantly by Leading Players 2023 to 2028on January 19, 2023 at 3:11 am
Pages Report] Rising demand for Pharma & Healthcare Industry will drive the Cystic Fibrosis (CF) Therapeutics segment growth over the next five years. Global Market Analysis ...
- Global Cystic Fibrosis Market will reach US$ 24.35 Billion by 2028on January 18, 2023 at 10:20 am
According to the research. Cystic Fibrosis is an ongoing genetic disease that affects the lungs and other body systems (Pancreas, Liver, and Kidney) and for which there is currently no cure. It mainly ...
- Cystic Fibrosis Market Size to reach USD 31.88 billion by 2027-Fortune Business Insightson January 18, 2023 at 12:03 am
The market for cystic fibrosis, which was valued at USD 5.12 billion in 2019, is anticipated to grow to USD 31.88 ...
- New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Updateon January 17, 2023 at 4:32 pm
Board certified in pediatrics and pediatric pulmonology, Dr. Gross previously served as Affiliate Cystic Fibrosis Center Director at Tripler Army Medical Center and Madigan Army Medical Center and ...
- I'm a travel photographer with Cystic Fibrosis – here's what I've learned about chasing your dreamson January 16, 2023 at 9:15 am
Travel photography is a chance to escape the every day, explore new cultures and immerse yourself in new experiences. But it also comes with challenges. You have to navigate in a new place, and adapt ...
The Latest Google Headlines on:
Cystic fibrosis
[google_news title=”” keyword=”Cystic fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Cystic fibrosis treatment
- New genetic disorder that causes susceptibility to opportunistic infectionson January 21, 2023 at 3:03 pm
Immunogeneticists have discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including a life-threatening fungal pneumonia.
- Cystic Fibrosis Carrier: What You Need to Knowon January 19, 2023 at 4:00 pm
What is a cystic fibrosis carrier? Cystic fibrosis is an inherited disease that affects the glands that make mucus and sweat. Children may be born with cystic fibrosis if each parent carries one ...
- Is There a Cure for Cystic Fibrosis?on January 19, 2023 at 4:00 pm
These organizations include: Cystic Fibrosis Foundation: CFF is a Better Business Bureau-accredited organization that works to fund research for a cure and advanced treatments. Cystic Fibrosis ...
- Global Cystic Fibrosis Market will reach US$ 24.35 Billion by 2028on January 18, 2023 at 10:20 am
According to the research. Cystic Fibrosis is an ongoing genetic disease that affects the lungs and other body systems (Pancreas, Liver, and Kidney) and for which there is currently no cure. It mainly ...
- Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosison January 18, 2023 at 3:04 am
Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the ...
- New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Updateon January 17, 2023 at 4:32 pm
event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate ...
- New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Updateon January 17, 2023 at 4:32 pm
event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate ...
- New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Updateon January 17, 2023 at 4:32 pm
event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate ...
- New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Updateon January 17, 2023 at 1:42 pm
event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company's Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate with ...
- Cystic Fibrosis Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsighton January 16, 2023 at 1:49 pm
This biofilm disruption is believed to improve antibiotic effectiveness by increasing exposure of bacteria to antibiotics. It is in Phase 2 stage of development for the treatment of Cystic Fibrosis.
The Latest Google Headlines on:
Cystic fibrosis treatment
[google_news title=”” keyword=”cystic fibrosis treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]